SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: PK who wrote (820)5/6/1998 11:16:00 PM
From: Zhaohui Chen  Read Replies (3) of 2135
 
Intrinsic disadvantage of those two protein-based drugs, if indeed proven effective for solid tumors in human, is their requirement of tumor-site specific delivery. In other word, those drugs need special guidance vehicle to carry them to the targets, which has been very very difficult to do even with advanced science and technology. It is easy for scientist to inject the drugs into tumors in mice directly, but it will be very difficult to apply the drugs to humans the same way.

I believe that these two drugs has quite few years away before they can make money for their fans; When they do, their potentials are quite limited due to lack of site-specific delivery vehicles.

At 30ish, ENMD is still over priced.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News